Andreas Krämer graduated with a diploma in Chemistry from the University of Freiburg in 2012. During his PhD thesis at the University of Darmstadt (2013-2017), he focused on structural studies of bacterial members of the histone deacetylase superfamily (HDAC). After completing his PhD, he joined the group led by Stefan Knapp at the SGC Frankfurt as a postdoc, where he was funded by the Wellcome Trust, working on the structure-based development of selective and potent CaMK1D kinase inhibitors for the treatment of highly aggressive subtypes of breast cancer. Afterwards he worked at the Frankfurt Cancer Institute (FCI) as a staff scientist where, among other things, he was responsible for developing a comprehensive screening platform for kinases. In the beginning of 2022, Andreas became a principal investigator and is responsible for running the X-ray crystallography facility unit. His current research interests focus primarily on the structural biology of kinases and E3 ligases.
Wu Q, Heidenreich D, Zhou S, Ackloo S, Krämer A, Nakka K, Lima-Fernandes E, Deblois G, Duan S, Vellanki RN, Li F, Vedadi M, Dilworth J, Lupien M, Brennan PE, Arrowsmith CH, Müller S, Fedorov O, Filippakopoulos P, Knapp S
Nat Commun. 2019-4-23 . 10(1):1915 .doi: 10.1038/s41467-019-09672-2
PMID: 31015424